Susan F. Slovin, MD, PhD, discusses selecting among available treatment options for patients with metastatic castration-sensitive prostate cancer.
Susan Slovin, MD, PhD, Memorial Sloan Kettering Cancer Center
Advertisement
Articles by Susan Slovin, MD, PhD, Memorial Sloan Kettering Cancer Center
Advertisement
Latest Updated Articles
Dr. Slovin on Selecting Among Available Treatment Options in mCSPCPublished: August 24th 2021 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
The OncFive: Top Oncology Articles for the Week of 1/25
3
FDA Approval Sought for Lirafugratinib in Second-Line, FGFR2-Altered Cholangiocarcinoma
4
Multi-Omic Profiling Reveals Genetic and Epigenetic Pirtobrutinib Resistance Pathways in MCL
5